NCE-1 Intelligence & Market Opportunity

Vafseo

Vadadustat

Antianemic

Oral Tablets

Vafseo is an oral tablet that treats anemia in adults with chronic kidney disease on dialysis by boosting natural erythropoietin production through HIF‑prolyl hydroxylase inhibition. It minimizes the need for blood transfusions while carrying a caution for cardiovascular and clotting risks .

Approval Date

27-Mar-24

NCE-1 Date

27-Mar-28

NCE Date

27-Mar-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.6073

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

148

2027

165

2028

242

2029

307

2030

364

2031

431

2032

492

Molecule profile

Details & specifications

Molecule

Vadadustat

Innovator

AKEBIA THERAPEUTICS INC

Dosage Form

Oral Tablets

Strength

150 mg, 300 mg and 450 mg tablet

Therapeutic Category

Antianemic

Usage

To treat anemia due to chronic kidney disease

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.